Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.81 - $14.38
Previous CloseN/A
Volume116.12K
Average Volume (3M)534.25K
Market Cap
$601.08M
Enterprise Value$831.80M
Total Cash (Recent Filing)$32.91M
Total Debt (Recent Filing)$341.24M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 11, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding66,892,300
10 Day Avg. Volume524,462
30 Day Avg. Volume534,255
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda9.85
Forecast
1Y Price Target
$14.67Price Target Upside95.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCash flow from operations materially increased 71% to nearly $26M, indicating strong financial performance.
Growth StrategyBioventus has set in place levers to drive both short and long-term growth and expects a back-half improvement in its growth rate.
ValuationBioventus is trading at an attractive valuation, at half the multiple of its small-cap MedTech peers, supporting the analyst's recommendation to maintain a BUY rating.
Bears Say
Adjusted EBITDA ConcernsAdjusted EBITDA should also be weaker given these revenue headwinds, tough adjusted EBITDA comp in the 1H, and more normalized expense levels expected vs. the reduced spending BVS operated under one year ago.
Pain Treatments SegmentPain Treatments growth benefited from a few million dollars of above-normal distributor orders, which is expected to negatively impact Q1 expectations as lower distributor orders are anticipated.
Revenue ChallengesQ1/H1 organic revenues should be more challenged given two fewer selling days in the Q1, pull-forward of HA orders from the Q1/25 to Q4/24, and continued BGS distributor choppiness for a couple more Qs.
Bioventus News
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $5.81 and its highest was $14.38 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $601.08M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is Nov 11, 2025 which is in 74 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Aug 06, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.157 by $0.053.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.11.
How many shares outstanding does Bioventus have?
Bioventus has 66,892,300 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.21 in its last earnings report, beating expectations of $0.157. Following the earnings report the stock price went up 18.73%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
Bioventus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (95.86% Upside)
$14.67 (95.86% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.46%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
-10.78%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. (BVS) is a medical device company that specializes in developing and commercializing clinically effective and cost-efficient solutions for bone healing, bone graft, joint therapies, and biologics. The company primarily operates in the healthcare sector, focusing on orthopedic solutions that enhance patient outcomes and reduce healthcare costs. Bioventus offers a diverse portfolio of products, including minimally invasive therapies for osteoarthritis, bone graft substitutes, and devices that stimulate bone growth.
BVS Company Deck
BVS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong financial results, strategic growth in key business areas, and significant opportunities from new product clearances. However, challenges from divestiture impacts, foreign exchange losses, and tariff headwinds were acknowledged.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$14.67
▲(95.86% Upside)
Technical Analysis
Ownership Overview
31.90% Insiders
8.25% Mutual Funds
46.04% Other Institutional Investors
5.37% Public Companies and
Individual Investors